ES2111002T3 - Factor activador de macrofagos derivado de la proteina de fijacion de vitamina d. - Google Patents

Factor activador de macrofagos derivado de la proteina de fijacion de vitamina d.

Info

Publication number
ES2111002T3
ES2111002T3 ES91917591T ES91917591T ES2111002T3 ES 2111002 T3 ES2111002 T3 ES 2111002T3 ES 91917591 T ES91917591 T ES 91917591T ES 91917591 T ES91917591 T ES 91917591T ES 2111002 T3 ES2111002 T3 ES 2111002T3
Authority
ES
Spain
Prior art keywords
macrophagus
vitamin
activating factor
factor derived
fixation protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91917591T
Other languages
English (en)
Inventor
Nobuto Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2111002T3 publication Critical patent/ES2111002T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

SE PRESENTA UN NUEVO Y POTENTE FACTOR DE ACTIVACION DE MACROFAGOS QUE SE PREPARA IN VITRO TRATANDO UN COMPONENTE ESPECIFICO DEL GRUPO HUMANO, TAMBIEN CONOCIDO COMO PROTEINA DE UNION DE LA VITAMINA D HUMANA, CON GLICOSIDASAS. EL COMPONENTE ESPECIFICO DE GRUPO, QUE SE AISLA A PARTIR DE LA SANGRE OBTENIDA POR PROCEDIMIENTOS CONOCIDOS, SE CONVIERTE DE ESTA FORMA EN UN FACTOR ACTIVADOR DE MACROFAGOS ALTAMENTE POTENTES.
ES91917591T 1990-08-31 1991-08-29 Factor activador de macrofagos derivado de la proteina de fijacion de vitamina d. Expired - Lifetime ES2111002T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/576,248 US5177002A (en) 1989-11-20 1990-08-31 In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor

Publications (1)

Publication Number Publication Date
ES2111002T3 true ES2111002T3 (es) 1998-03-01

Family

ID=24303582

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91917591T Expired - Lifetime ES2111002T3 (es) 1990-08-31 1991-08-29 Factor activador de macrofagos derivado de la proteina de fijacion de vitamina d.

Country Status (9)

Country Link
US (1) US5177002A (es)
EP (1) EP0546096B1 (es)
JP (1) JP2596491B2 (es)
AT (1) ATE161580T1 (es)
AU (1) AU8654191A (es)
CA (1) CA2092720C (es)
DE (1) DE69128535T2 (es)
ES (1) ES2111002T3 (es)
WO (1) WO1992004459A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326749A (en) * 1989-11-20 1994-07-05 Nobuto Yamamoto Macrophage activating factor from vitamin D binding protein
US5177001A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor
US5627029A (en) * 1991-05-03 1997-05-06 Genzyme Corporation Method for obtaining informative cells
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
US5641747A (en) * 1994-07-25 1997-06-24 Temple University-Of The Commonwealth System Of Higher Education Treatment of osteopetrotic diseases
US20060014143A1 (en) * 1995-06-07 2006-01-19 Nobuto Yamamoto Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis
US6410269B1 (en) * 1995-06-07 2002-06-25 Nobuto Yamamoto Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis
EP1280546A4 (en) * 2000-05-09 2005-02-23 Childrens Medical Center METHOD AND COMPOSITION FOR THE TREATMENT OF ANGIOGENESIS
CA2456843A1 (en) * 2001-08-14 2003-02-27 Statens Serum Institut A purification process for large scale production of gc-globulin, product obtained thereby and their use in medicine
JP5860401B2 (ja) * 2010-09-03 2016-02-16 森田薬品工業株式会社 新規Ｇｃグロブリンガラクトース脱糖体の製造方法
CN103547280B (zh) 2011-04-07 2017-06-09 艾弗兰纳特有限公司 用于药物组合物的巨噬细胞活化因子
AU2013323472B2 (en) * 2012-09-28 2018-07-05 Ellis KLINE Glycosidase regimen for treatment of infectious disease
US20160120946A1 (en) * 2013-06-09 2016-05-05 Efranat Ltd. Compositions comprising gc-macrophage activating factor and uses thereof
WO2019117295A1 (ja) * 2017-12-15 2019-06-20 公益財団法人神戸医療産業都市推進機構 活性型ＧｃＭＡＦの製造方法
AU2021398261A1 (en) * 2020-12-08 2023-07-06 Saisei Pharma Co., Ltd. Macrophage activator

Also Published As

Publication number Publication date
WO1992004459A1 (en) 1992-03-19
AU8654191A (en) 1992-03-30
CA2092720A1 (en) 1992-03-01
EP0546096A4 (es) 1994-04-27
DE69128535T2 (de) 1998-05-20
ATE161580T1 (de) 1998-01-15
DE69128535D1 (de) 1998-02-05
EP0546096B1 (en) 1997-12-29
JPH06503716A (ja) 1994-04-28
US5177002A (en) 1993-01-05
EP0546096A1 (en) 1993-06-16
JP2596491B2 (ja) 1997-04-02
CA2092720C (en) 1999-12-14

Similar Documents

Publication Publication Date Title
ES2111002T3 (es) Factor activador de macrofagos derivado de la proteina de fijacion de vitamina d.
ES2173873T3 (es) Utilizacion de anticuerpos anti-vegf para el tratammiento del cancer.
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
ATE165395T1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
MX162688A (es) Suturas compuestas de seda y elastomeros termoplasticos hidrofobos
SG170730A1 (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
EP0831885A4 (en) METHOD AND USE OF TISSUE GROWTH FACTOR AS AN INDUCING AGENT
IL127558A0 (en) Hepatocyte growth factor receptor agonists and uses thereof
ATE224213T1 (de) Implantat aus resorbierbaren phosphatglas
DK0429570T3 (da) Osteoinducerende præparater
NL300353I1 (nl) Geneesmiddelen met monoclonale antilichamen, die specifiek zijn voor de menselijk epidermale groeifactorreceptor
AR003989A1 (es) Composicion cosmetica o farmaceutica y procedimiento de tratamiento cosmetico, excluido tdo tratamiento terapeutico que utiliza la composicion cosmetica.
DK275482A (da) Medicinske klaebeark til behandling af hjertesygdomme samt fremgangsmaade til fremstilling deraf
ATE296839T1 (de) Antikörper zur krebsbehandlung und -diagnose
FI902245A0 (fi) Nytt antikroppsdistributionssystem foer modifierare av biologisk respons.
BR9712259A (pt) Colostrininin, uso do mesmo, processos de tratar distúrbios do sistema nervoso central e/ou do sistema imune, de preparar colostrinin de colostro de mamìferos e de produzir uma composição farmacêutica, composição farmacêutica, suplemento dietético, nanopeptìdeo, e, uso do mesmo.
DE3788231D1 (de) Kosmetisches mittel und zusammensetzung zur behandlung der haut.
NO883306D0 (no) Farmasoeytisk aktive konjugater med forbedret bindingsspesifisitet for kroppsvev.
EP1594895A4 (en) GROWTH FACTOR COMPLEXES AND MODULATION OF CELL MIGRATION AND GROWTH
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
ES2128348T3 (es) Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular.
ES2101695T3 (es) Haptoglobina relacionada con el cancer (hpr).
AR031641A1 (es) Combinacion inmunoterapeutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
Jang et al. Injectable in situ–forming silk fibroin–based hydrogel dressing with MXene/polydeoxyribonucleotide for wound protection and regeneration

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 546096

Country of ref document: ES